[youtube-video]https://youtu.be/30vqKAxikwo?si=O1nxBSiogYyFDvgT[/youtube-video]
Dr. Chinmay Jani from University of Miami in conversation with Dr. Rahul Aggarwal from UCSF Hellen Diller Family Comprehensive Cancer Center
Dr. Aggarwal shared his expertise on the use of Abiraterone, the selection of androgen receptor pathway inhibitors (ARPI), and the importance of genetic testing in prostate cancer management.
In this episode, we cover:
• When to use Abiraterone for high-risk patients and its role in combination with ADT.
• The selection process between different ARPIs and the significance of overall survival in clinical trials.
• The considerations for triple therapy versus double therapy in high-risk metastatic patients.
• The necessity of both somatic tumor genomic testing and germline testing in prostate cancer patients.